
CMTA Invests $300,000 in Groundbreaking Gene Editing Therapy for CMT2A
GLENOLDEN, PA — The Charcot-Marie-Tooth Association (CMTA) has announced a $300,000 investment in a groundbreaking gene editing project aimed at tackling CMT2A, the most common axonal type of Charcot-Marie-Tooth disease. The …
CMTA Invests $300,000 in Groundbreaking Gene Editing Therapy for CMT2A Read More